Retatrutide appears to be a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By stimulating these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, and ultimately co